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A B S T R A C T   
Niemann-Pick type C (NPC) disease, a lysosomal storage disorder caused by defective NPC1/NPC2 function, 
results in the accumulation of cholesterol and glycosphingolipids in lysosomes of affected organs, such as liver 
and brain. Moreover, increase of mitochondrial cholesterol (mchol) content and impaired mitochondrial function 
and GSH depletion contribute to NPC disease. However, the underlying mechanism of mchol accumulation in 
NPC disease remains unknown. As STARD1 is crucial in intramitochondrial cholesterol trafficking and acid 
ceramidase (ACDase) has been shown to regulate STARD1, we explored the functional relationship between 
ACDase and STARD1 in NPC disease. Liver and brain of Npc1− /− mice presented a significant increase in mchol 
levels and STARD1 expression. U18666A, an amphiphilic sterol that inhibits lysosomal cholesterol efflux, 
increased mchol levels in hepatocytes from Stard1f/f mice but not Stard1ΔHep mice. We dissociate the induction of 
STARD1 expression from endoplasmic reticulum stress, and establish an inverse relationship between ACDase 
and STARD1 expression and LRH-1 levels. Hepatocytes from Npc1+/+ mice treated with U18666A exhibited 
increased mchol accumulation, STARD1 upregulation and decreased ACDase expression, effects that were 
reversed by cholesterol extraction with 2-hydroxypropyl-β-cyclodextrin. Moreover, transfection of fibroblasts 
from NPC patients with ACDase, decreased STARD1 expression and mchol accumulation, resulting in increased 
mitochondrial GSH levels, improved mitochondrial functional performance, decreased oxidative stress and 
protected NPC fibroblasts against oxidative stress-mediated cell death. Our results demonstrate a cholesterol- 
dependent inverse relationship between ACDase and STARD1 and provide a novel approach to target the 
accumulation of cholesterol in mitochondria in NPC disease.   
1. Introduction 
Niemann-Pick type C (NPC) disease is an inherited and progressive 
lysosomal storage disorder that exhibits a wide array of symptoms, 
ranging from neurological deterioration, liver disease, splenomegaly 
and ultimately premature death [1]. NPC disease is caused by mutations 
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in the genes encoding NPC1/NPC2, two lysosomal resident proteins that 
work in tandem in the regulation of lysosomal cholesterol homeostasis 
[2,3]. Moreover, disease-causing mutations on quality control pathways 
involving the lysosome and endoplasmic reticulum (ER) have also been 
shown to contribute to NPC disease [4]. Defects in NPC1 account for up 
to 95% of NPC cases and given its role in lysosomal cholesterol egress, 
the primary biochemical feature of NPC disease is reflected in the 
lysosomal accumulation of unesterified cholesterol in brain and liver [1, 
2,5]. Besides cholesterol, lysosomal accumulation of glycosphingolipids 
is an additional characteristic feature of NPC disease [2,6–8], and the 
prevention of this event is the basis of miglustat, an EMA-approved 
therapy for patients with NPC disease. 
In addition to lysosomes, cholesterol accumulation has also been 
reported in mitochondria of affected organs from Npc1− /− mice [9,10], a 
murine model which reproduces many of the pathological features of the 
human disease. Mitochondrial cholesterol accumulation has emerged as 
a critical factor in several diseases, including steatohepatitis, cancer or 
Alzheimer’s disease, due in part to the regulation of mitochondrial 
function and limitation of mitochondrial antioxidant defenses [10–16]. 
In particular, mitochondrial cholesterol accumulation is known to 
decrease mitochondrial GSH (mGSH) stores by impairing cytosolic GSH 
transport into mitochondria [12,13] and this outcome has been shown 
to determine mitochondrial dysfunction and oxidative stress in NPC 
disease [7]. Moreover, replenishment of mGSH levels improved mito-
chondrial function in cerebellum, abrogated oxidative stress and 
extended the median and maximal life span of Npc1− /− mice [7]. 
Therefore, given the key role of cholesterol in regulating mGSH trans-
port and associated consequences, understanding the molecular mech-
anisms involved in the trafficking of cholesterol to mitochondria may be 
of relevance in NPC disease. The trafficking of mitochondrial cholesterol 
is not well understood and involves different intracellular sources and 
different molecular players [17–19]. STARD3 (also known as MLN64) is 
thought to transfer cholesterol from endosomes to the mitochondrial 
outer membrane, and its overexpression has been shown to increase 
mitochondrial cholesterol levels in NPC cells [20]. However, targeted 
mutation of the MLN64 STAR domain results in modest alterations in 
cellular sterol metabolism [21]. On the other hand, STARD1, the 
founder member of the STAR family, plays a crucial role in the traf-
ficking of cholesterol to mitochondrial inner membrane, where its 
availability is the rate-limiting step in steroidogenesis [17–19]. More-
over, mice with global STARD1 deletion develop lethal congenital lipoid 
hyperplasia and knockout mice die within 7–10 days after birth [22], 
indicating that other STAR members cannot replace STARD1 function. 
In addition, hepatocyte-specific STARD1 ablation prevents 
acetaminophen-mediated hepatic mitochondrial cholesterol accumula-
tion without change in MLN64 expression [23]. Thus, while these 
findings indicate that STARD1 is key in the intramitochondrial traf-
ficking of cholesterol, the mechanism of STARD1 regulation in NPC 
disease has not been previously explored. As ER stress and acid ceram-
idase (ACDase), a lysosomal enzyme that regulates ceramide homeo-
stasis, have been shown to regulate STARD1 expression [23,24], our aim 
was to examine the contribution of ER stress and ACDase in STARD1 
expression in NPC disease and its impact in regulating mitochondrial 
cholesterol levels. Our findings show a cholesterol-dependent inverse 
relationship between ACDase and STARD1 and provide evidence that 
ACDase-mediated downregulation of mitochondrial cholesterol content 
by repressing STARD1 improves mitochondrial performance and 
oxidative stress in fibroblasts from patients with NPC disease. 
2. Results 
2.1. Hepatic mitochondrial cholesterol accumulation and STARD1 
upregulation in Npc1− /− mice 
Accumulation of cholesterol in lysosomes caused by mutations in 
NPC1 is a hallmark of NPC disease [1–5]. Besides this event, 
accumulation of cholesterol in mitochondria of affected organs from 
Npc1− /− mice has also been initially reported but not well characterized 
[9,10]. Hence, before exploring potential mechanisms, we further 
analyzed hepatic mitochondrial cholesterol homeostasis in Npc1− /−
mice. First, staining of liver sections with GST-PFO, which detects 
unesterified cholesterol levels in membranes [25], increased in liver 
from Npc1− /− mice compared to Npc1+/+ mice, with similar findings 
seen with filipin staining (Fig. 1A). These results were further confirmed 
by HPLC analyses of liver homogenates and isolated mitochondria from 
Npc1− /− mice (Fig. 1B and C). Consistent with the increase in mito-
chondrial cholesterol loading, fluorescence anisotropy analysis of liver 
mitochondria from Npc1− /− mice labeled with the fluorescent probe 
DPH revealed an increase in mitochondrial membrane order compared 
to mitochondria from Npc1+/+ mice (Fig. 1D). In addition, confocal 
microscopy analyses of primary mouse hepatocytes (PMH) from 6-week 
old Npc1− /− mice indicated increased filipin staining and colocalization 
with cytochrome c-labeled mitochondria (Fig. 1E and F), confirming 
that the increase in mitochondrial cholesterol levels occurs primarily in 
hepatocytes. As a potential mechanism accounting for the increase in 
mitochondrial cholesterol content, we examined the expression of 
STARD1, which plays a crucial role in the intramitochondrial cholesterol 
trafficking from the outer to inner mitochondrial membrane for meta-
bolism [17–19,21–23]. Remarkably, STARD1 expression increased at 
the protein and mRNA level in liver of Npc1− /− mice (Fig. 1G; Supple-
mentary Fig 1A). Moreover, expression of MLN64, an endosomal 
member of the STAR family involved in egress of cholesterol from 
endosomes to STARD1 in the mitochondrial outer membrane (18–20), 
increased in liver of Npc1− /− mice (Fig. 1G). These findings establish the 
increase in hepatic mitochondrial cholesterol levels that correlate with 
expression of STARD1. 
2.2. Hepatocyte-specific STARD1 deletion prevents U18666A-induced 
mitochondrial cholesterol accumulation 
Since hepatocyte-specific STARD1 ablation prevented hepatic mito-
chondrial cholesterol accumulation despite unchanged expression of 
MLN64 [23], we next focused on STARD1 and addressed its causal role 
in the accumulation of cholesterol to mitochondria, using an in vitro 
model of NPC1 using U18666A. U18666A is an amphiphilic cationic 
sterol that interferes with the trafficking of cholesterol and causes its 
increase in lysosomes, thus reproducing the NPC phenotype [26,27]. 
Incubation of HeLa cells with U18666A has been shown to cause the 
accumulation of cholesterol in mitochondria [28]. To test the role of 
STARD1 in mitochondrial cholesterol loading, we generated mice with 
STARD1 deletion in hepatocytes (Stard1ΔHep) mice that had been 
recently characterized [23]. Hepatocytes from Stard1f/f mice incubated 
with U18666A exhibited increased cholesterol trafficking in mitochon-
dria, as shown by confocal imaging analyses (Fig. 1H and I). However, 
U18666A-induced mitochondrial cholesterol accumulation was pre-
vented in hepatocytes from Stard1ΔHep mice (Fig. 1H and I). These 
findings provide a causal role for STARD1 in the trafficking of choles-
terol to mitochondria in NPC disease. 
2.3. Fibroblasts from patients with NPC disease exhibit increased 
mitochondrial cholesterol levels and STARD1 expression 
To validate the relevance of the preceding findings to human disease, 
we examined the homeostasis of mitochondrial cholesterol in fibroblasts 
from patients with NPC disease. In line with findings in liver, fibroblasts 
from patients with NPC disease (Npc− /-) exhibited increased unesteri-
fied cholesterol levels determined by HPLC analysis in homogenate and 
isolated mitochondria compared to fibroblasts from control subjects 
(Npc+/+) (Fig. 2A and B). Furthermore, confocal microscopy analyses of 
Npc− /- fibroblasts revealed mitochondrial unesterified cholesterol 
accumulation with respect to Npc+/+ fibroblasts, as indicated by the 
colocalization of filipin and cytochrome c staining (Fig. 2C and D). 
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Furthermore, consistent with the enrichment in cholesterol, fluores-
cence anisotropy of mitochondria from Npc− /- fibroblasts labeled with 
DPH revealed increased order parameter (not shown). Moreover, 
STARD1 increased at the mRNA and protein levels in Npc− /- fibroblasts 
from patients with NPC disease compared to control Npc+/+ fibroblasts 
(Fig. 2E; Supplementary Fig 1B). Thus, these findings confirm the 
Fig. 1. Mitochondrial cholesterol trafficking and StARD1 expression in livers of Npc1¡/¡ mice. Npc1þ/þ and Npc1¡/¡ mice were sacrificed at 6 weeks of 
age to isolate mitochondria from liver. (A) Filipin and GST-PFO staining. (B) Homogenate and (C) mitochondrial cholesterol levels by HPLC analyses. (D) 
Mitochondrial membrane order measured by DPH fluorescence anisotropy. (E) Cytochrome c and Filipin co-staining for confocal microscopy analyses of Npc1+/+ and 
Npc1− /− primary mouse hepatocytes. (F) Staining markers colocalization analysis using Image J software. (G) Western blot analyses and quantification of the 
mitochondrial cholesterol carriers StARD1 and MLN64 in liver of 6-weeks old Npc1+/+ and Npc1− /− mice. Data are presented as means ± SEM (n > 4, Unpaired 
Student’s t-test (two-tailed)). *p < 0.05, **p < 0.01, ***<0.001 vs. Npc1+/+. (H-I) Primary mouse hepatocytes from StARD1f/f and StARD1ΔHep mice were treated 
with U18666A (U18, 2 μg/μl, 16 h) to determine (H) Cytochrome c and Filipin co-staining for confocal microscopy analyses and (I) Quantification of staining markers 
colocalization analysis using Image J software. Data are presented as means ± SEM (n > 3, One-way ANOVA followed byTukey’s Multiple Comparison test). *p <
0.05 vs NT. 
Fig. 2. Mitochondrial cholesterol trafficking and StARD1 expression in human skin fibroblasts from control subjects or patients with NPC disease. (A) 
Homogenate and (B) mitochondrial cholesterol levels by HPLC analyses. (C) Cytochrome c and Filipin co-staining for confocal microscopy analyses. (D) Staining 
markers colocalization analysis using Image J software. (E) Western blot analyses and quantification of the mitochondrial cholesterol carrier StARD1. Data are 
presented as means ± SEM (n > 5, Unpaired Student’s t-test (two-tailed)). **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. Npc1+/+. 
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outcome observed in liver from Npc1− /− mice and reveal the mito-
chondrial cholesterol accumulation in human NPC disease. 
2.4. Livers from Npc1− /− mice and fibroblasts from NPC patients exhibit 
decreased ACDase expression without evidence of ER stress 
Given the relevance of STARD1 in the trafficking of cholesterol to 
mitochondrial inner membrane [22,23], we next examined potential 
mechanisms involved in the upregulation of STARD1 in NPC disease. ER 
stress has been shown to stimulate the transcriptional upregulation of 
STARD1 independently of SREBP activation [23,29], and hence we 
analyzed the expression of ER stress markers in liver from Npc1− /− mice 
and Npc− /- fibroblasts from patients with NPC disease. While tunica-
mycin induced markers of ER stress (BIP, PDI and CHOP) in control 
Npc+/+ fibroblasts (Supplemetary Figure 2), the levels of ER stress 
markers BIP, PDI, CHOP, p-EIF2α and s-XBP1 in liver fractions from 
Npc1− /− mice or Npc− /- fibroblasts from patients with NPC disease were 
similar to those seen in Npc1+/+ mice or control Npc+/+ fibroblasts 
(Fig. 3A). These findings are in line with previous reports indicating that 
ER stress appears to play a minor role in lysosomal storage disorders, 
including NPC disease [30]. Given this outcome, we searched for 
alternative mechanisms involved in STARD1 regulation. As STARD1 is 
also regulated by steroidogenic factor 1 (SF-1), a member of the nuclear 
receptor family, and ACDase has been shown to repress SF-1 and sub-
sequently STARD1 upregulation [24], we next examined ACDase 
expression in livers from Npc1− /− mice and Npc− /- fibroblasts from 
patients with NPC disease. Interestingly, the expression of ACDase 
decreased in liver and Npc− /- fibroblasts from NPC patients (Fig. 3B) and 
was further confirmed by confocal microscopy analyses in PMH from 
Npc1− /− mice and Npc− /- fibroblasts (Supplementary Fig 3A–D). Inter-
estingly, the decreased level of ACDase protein was not due to impaired 
transcription, as the levels of mRNA in affected tissues of Npc1− /− mice 
or Npc fibroblasts were similar to control counterparts (Supplemetary 
Figure 4). These findings suggest that ACDase is regulated post-
transcriptionally in NPC disease, consistent with the effect of MG132, a 
proteasome inhibitor, in increasing ACDase protein levels in human 
prostate cancer cells [31]. Moreover, as liver receptor homolog 1 
(LRH-1), another member of the nuclear receptor family highly related 
to SF-1, regulates STARD1 [32], we examined its expression in NPC 
disease. As seen, LRH-1 levels increased in liver from Npc1− /− mice and 
in Npc− /− fibroblasts from NPC patients (Supplemetary Figure 5). Thus, 
these data revealed for the first time an inverse correlation between 
ACDase and STARD1 expression in NPC disease. 
2.5. Mitochondrial cholesterol status and expression of STARD1 and 
ACDase in brain and cerebellum from Npc1− /− mice 
We next examined the cholesterol homeostasis in brain homogenate 
from Npc1− /− mice. In contrast to liver, brain homogenate from Npc1− /−
mice exhibited lower unesterified cholesterol levels compared to Npc1+/ 
+ mice, as revealed by filipin and GST-PFO staining or HPLC analyses 
(Supplementary Figure 6A, B), with similar findings observed in cere-
bellum from Npc1− /− mice (Supplementary Figure 7A, B). Since myelin 
is the major source of cholesterol in the brain, these findings are 
consistent with previous reports showing that in NPC disease cholesterol 
accumulates in most tissues but not the brain due to the extensive 
demyelination that occurs in this disease [33–36]. Quite interestingly, 
however, despite lack of increase of cholesterol levels in brain homog-
enate, isolated brain mitochondria exhibited increased mitochondrial 
cholesterol accumulation that resulted in increased mitochondrial 
membrane order (Supplementary Figure 6C, D), indicating the activa-
tion of a specific mechanism leading to increased mitochondrial 
cholesterol trafficking. Indeed, expression of STARD1 increased 4-fold in 
brain and cerebellum from Npc1− /− mice (Supplementary Figure 6E; 
Supplementary Figure 7C). In agreement with findings in liver, brain or 
cerebellum from Npc1− /− mice failed to exhibit signs of ER stress as 
revealed by the expression of BIP, PDI, CHOP, sXBP-1 and p-EIF2 
(Supplementary Figure 6F; Supplementary Figure 7D). However, 
decreased levels of ACDase were observed in brain or cerebellum from 
Npc1− /− mice (Supplementary Figure 6G; Supplementary Figure 7E), in 
line with findings in liver. Overall these results confirm the accumula-
tion of mitochondrial cholesterol in brain and cerebellum from Npc1− /−
mice and further establish an inverse relationship between STARD1 and 
ACDase in these affected organs. 
2.6. U18666A reproduces the inverse correlation between STARD and 
ACDase in Npc1+/+ PMH 
We next further characterized the relationship between STARD1 and 
ACDase. Since ACDase is a lysosomal enzyme, we first addressed 
whether the decrease in ACDase expression in NPC cells could be a 
consequence of the accumulation of cholesterol in lysosomes. Hence, we 
used the amphiphilic aminosteroid U186661, which antagonizes NPC1 
and increases intracellular cholesterol accumulation. Confocal imaging 
analysis of PMH from Npc1+/+ mice stained with filipin and Lamp2 
revealed that U18666A significantly increased lysosomal cholesterol 
accumulation, reproducing the primary feature of NPC disease (Fig. 4A). 
In addition, U18666A also stimulated the accumulation of cholesterol in 
mitochondria, as seen by the colocalization of filipin and Cyt C staining 
of Npc1+/+ PMH (Fig. 4B), in line with the findings seen in Npc1− /−
PMH. Moreover, similar accumulation of mitochondrial cholesterol was 
observed in Npc+/+ fibroblasts upon U18666A treatment (Fig. 5A and 
B). Interestingly, U18666A treatment significantly increased STARD1 in 
both PMH from Npc1+/+ mice (Fig. 4C) and Npc+/+ fibroblasts (Fig. 5C). 
In addition, in line with preceding findings in liver or brain tissues, 
U18666A treatment decreased the expression of ACDase in PMH from 
Npc1+/+ mice (Fig. 4C) or control Npc+/+ fibroblasts (Fig. 5C). Incu-
bation of Npc1+/+ PMH with U18666A failed to induce ER stress 
markers (Fig. 4D), consistent with findings in Npc1− /− PMH. Thus, these 
results provide evidence for a link between lysosomal cholesterol 
accumulation with ACDase repression and enhanced STARD1 
expression. 
2.7. 2-hydroxypropyl-β-cyclodextrin prevents U18666A-mediated 
ACDase downregulation and STARD1 upregulation 
To further establish the role of cholesterol in the relationship be-
tween STARD1 and ACDase, we next examined the impact of 2- 
hydroxypropyl-β-cyclodextrin (HMβCD) in the expression of ACDase 
and STARD1 in response to U18666A. Treatment of Npc+/+ fibroblasts 
from control patients or PMH from Npc1+/+ mice with HMβCD pre-
vented U18666A-induced cholesterol accumulation and trafficking to 
mitochondria in both cell types (Fig. 5A and B; Fig. 6A). Moreover, this 
outcome paralleled the ability of HMβCD to reverse the increase of 
STARD1 and the repression of ACDase induced by U18666A in control 
Npc+/+ fibroblasts and PMH from Npc1+/+ mice (Figs. 5C and 6B). PMH 
from Npc1− /− mice and Npc− /- fibroblasts from NPC patients exhibited 
the same changes induced by HMβCD regarding the reversed relation-
ship between the expression levels of STARD1 and ACDase and the 
impact in mitochondrial cholesterol increase (Fig. 6C and D and Sup-
plemetary Figure 8). These findings further establish a cholesterol- 
dependent relationship between STARD1 and ACDase. 
2.8. ACDase overexpression in fibroblasts from NPC patients prevents 
STARD1 upregulation and mitochondrial cholesterol accumulation 
To examine the cause-and-effect relationship between the decreased 
expression of ACDase and the induction of StARD1, we analyzed 
whether ACDase overexpression impact the regulation of STARD1. For 
this purpose, Npc− /- fibroblasts from NPC patients were transfected with 
cDNA encoding ACDase (MGC Human ASAH1 Sequence-Verified cDNA 
Accession: BC016481). Compared to transfection with scrambled 
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Fig. 3. ACDase and ER stress markers protein expression in livers from Npc1¡/¡ mice and fibroblasts from NPC patients. A) ER stress markers and (B) 
ACDase protein expression analyzed by Western blot. Data are presented as means ± SEM (n > 3, Unpaired Student’s t-test (two-tailed)). ***p < 0.001, ****p <
0.0001 vs. Npc1+/+. 
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Fig. 4. Effects of U18666A treatment on liver mitochondrial cholesterol trafficking. Primary mouse hepatocytes from Npc1+/+ were treated with U18666A (2 
μg/μl, 16 h) to determine (A) Lysosomes and Filipin co-staining, (B) Mitochondria and Filipin co-staining for confocal microscopy analyses. Staining markers 
colocalization analysis using Image J software. (C) StARD1, ACDase and (D) ER stress markers protein expression analyzed by Western blot. Data are presented as 
means ± SEM (n > 5, Unpaired Student’s t-test (two-tailed)). *p < 0.05, ***p < 0.001 vs. Control. 
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control GFP vector, ACDase transfection resulted in a 30-fold increase in 
ACDase expression (Fig. 7A), which translated in significantly higher 
ACDase protein levels (Fig. 7B). ACDase overexpression markedly 
decreased the expression of STARD1 in Npc− /- fibroblasts (Fig. 7B). 
Interestingly, given the role of LRH-1 in the transcriptional activation of 
STARD1, ACDase transfection repressed the expression of LRH-1 in 
Npc− /- fibroblasts from patients with NPC disease (Fig. 7C). To deter-
mine the impact of ACDase overexpression on the trafficking and 
accumulation of cholesterol in mitochondria, we performed confocal 
microscopy analyses of Npc− /- fibroblasts transfected with ACDase. 
Npc− /- fibroblasts from patients with NPC disease exhibited lower 
mitochondrial unesterified cholesterol levels as indicated by the coloc-
alization of filipin with Cyt C staining, compared to scrambled control- 
GFP transfected fibroblasts (Fig. 7D). These findings indicate that 
ACDase expression represses STARD1 upregulation and decreases 
mitochondrial cholesterol accumulation in human NPC disease. 
2.9. ACDase overexpression in fibroblasts from NPC patients increases 
mGSH, improves mitochondrial function and protects against oxidative 
stress and cell death 
We next examined the functional impact of ACDase overexpression 
Fig. 5. Effects of U18666A on mitochondrial cholesterol trafficking and HMβCD modulation in human fibroblasts. Fibroblasts from control patients treated 
with U18666A (2 μg/μl, 16 h) were co-treated with HMβCD (2 mM, 16 h) to determine (A) Mitochondria and Filipin co-staining for confocal microscopy analyses. (B) 
Staining markers colocalization analysis using Image J software. (C) StARD1, and ACDase protein expression analyzed by Western blot. Data are presented as means 
± SEM (n > 5, Unpaired Student’s t-test (two-tailed)). *p < 0.05, **p < 0.01, ****p < 0.0001 vs. U18666A or control. 
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Fig. 6. Effects of HMβCD on hepatocytes from Npc1þ/þmice treated with U18666A. Primary mouse hepatocytes from Npc1+/+ treated with U18666A (2 μg/μl, 
16 h) and primary mouse hepatocytes from Npc1− /− were co-treated with HMβCD (2 mM, 16 h) to determine (A–C) Mitochondria and Filipin co-staining for confocal 
microscopy analyses. Staining markers colocalization analysis using Image J software. (B–D) StARD1, and ACDase protein expression analyzed by Western blot. Data 
are presented as means ± SEM (n > 5, Unpaired Student’s t-test (two-tailed)). *p < 0.05, **p < 0.01 vs. U18666A or Npc1− /− . 
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Fig. 7. ACDase overexpression in fibroblasts from NPC patients. Fibroblasts from NPC patients were transfected with a sobrexpression ACDase vector or the 
scrambled control-GFP vector to analyze (A) GFP and ACDase mRNA expression and (B) StARD1, and ACDase protein expression by Western blot. (C) LRH expression 
in fibroblasts from patients with NPC disease. Data are presented as means ± SEM (n = 3, Unpaired Student’s t-test (two-tailed)). (D) Mitochondria and Filipin co- 
staining for confocal microscopy analyses. Staining markers colocalization analysis using Image J software. Data are presented as means ± SEM (n > 5, Unpaired 
Student’s t-test (two-tailed)). *p < 0.05, **p < 0.01 vs. control GFP. 
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Fig. 8. ACDase overexpression improves mitochondrial function, and protects against oxidant cell death in fibroblasts from NPC patients. Fibroblasts from 
NPC patients were transfected with the ACDase vector or the scrambled control-GFP vector to analyze (A) mitochondrial GSH levels after cell fractionation by 
digitonin permeabilization, (B), porin levels to monitor mitochondrial mass, (C–D) oxygen consumption by Seahorse XF analyser and (E–G) ROS production and cell 
viability after treatment with H2O2 1 mM for 24 h followed by CellROX Deep Red absorbance and Höechst imaging respectively. Data are presented as means ± SEM 
(n = 3, Unpaired Student’s t-test (two-tailed) or Two-way ANOVA test). *p < 0.05 vs NT or Npc1+/+. (For interpretation of the references to colour in this figure 
legend, the reader is referred to the Web version of this article.) 
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in fibroblasts from NPC patients. Consistent with the ability of ACDase to 
decrease STARD1 expression and mitochondrial cholesterol accumula-
tion (Fig. 7), Npc− /- fibroblasts from patients with NPC transfected with 
ACDase exhibited increased mGSH levels compared to fibroblasts 
transfected with control GFP vector (Fig. 8A). This outcome was not due 
to increased mitochondrial mass by ACDase overexpression as indicated 
by the unchanged levels of porin (Fig. 8B). Moreover, ACDase expression 
increased real-time oxygen consumption rates determined by an extra-
cellular flux analyser compared to Npc− /- fibroblasts from NPC patients 
transfected with control GFP control vector (Fig. 8C), leading to 
enhanced rates of basal respiration, ATP production and maximal 
respiration (Fig. 8D). Furthermore, ACDase transfection also resulted in 
decreased oxidative stress in response to H2O2 challenge as revealed by 
lower CellROX Deep Red fluorescence compared to Npc− /- fibroblasts 
from NPC patients transfected with control GFP vector (Fig. 8E). In line 
with these observations, Npc− /- fibroblasts from NPC patients trans-
fected with control GFP vector were sensitive to H2O2-induced oxidative 
cell death and this outcome was ameliorated by ACDase transfection 
(Fig. 8F and G), consistent with the replenishment of mGSH levels and 
attenuation of DCF fluorescence. Overall, these findings indicate that 
expression of ACDase has important functional consequences in fibro-
blasts from NPC patients. 
3. Discussion 
While the accumulation of cholesterol in lysosomes is a primary 
event in NPC disease and believed to promote disease progression, the 
disturbance of intracellular cholesterol trafficking is more extensive and 
affects other intracellular organelles. Here we further characterized the 
accumulation of cholesterol in mitochondria at the molecular level and 
provide evidence for a previously unrecognized relationship between 
ACDase and STARD1. Extending previous work focused on the role of 
mGSH depletion in NPC disease [7], we show increased mitochondrial 
cholesterol levels in the affected organs of Npc1− /− mice and in fibro-
blasts from NPC patients and its correlation with the expression of 
STARD1. While these members of the STAR family may work in tandem 
in the trafficking of cholesterol to mitochondria with MLN64 assisting in 
the mobilization of cholesterol from the ER to mitochondrial outer 
membrane [17–19], the action of STARD1 is crucial for the intra-
mitochondrial cholesterol distribution to the inner membrane for 
metabolism. Although forced MLN64 overexpression results in mito-
chondrial cholesterol accumulation [20], global deletion of STARD1 in 
mice results in lethal congenital lipoid hyperplasia [22], arguing that in 
the absence of STARD1 other members of the family cannot compensate 
for the trafficking of cholesterol to mitochondrial inner membrane for 
metabolism and generation of steroid hormones. Moreover, 
hepatocyte-specific STARD1 deletion has been shown to prevent mito-
chondrial cholesterol accumulation in acetaminophen-mediated liver 
failure despite unchanged MLN64 expression [23]. In line with these 
findings, we provide evidence for a causal role of STARD1 in the accu-
mulation of cholesterol in mitochondria, as this event is prevented in 
hepatocytes from Stard1ΔHep mice following exposure to U18666A, an 
amphiphilic sterol that reproduces the phenotype of NPC disease, 
including the accumulation of cholesterol in mitochondrial membranes 
[26–28]. 
Although ER stress has been shown to regulate STARD1 expression 
[23,29], the onset of ER stress is not a characteristic feature of NPC 
disease [30,37], and hence we searched for alternative mechanisms that 
could regulate STARD1 expression. We provide evidence for a previ-
ously unrecognized inverse relationship between ACDase and STARD1 
expression in NPC disease. Built on previous findings in adrenocortical 
cells showing that ACDase antagonizes SF-1 and represses target genes, 
including STARD1 [24], we show that the increased expression of 
STARD1 correlates with lower levels of ACDase in liver and brain from 
Npc1− /− mice and in fibroblast from NPC patients. Importantly, we show 
that increased lysosomal cholesterol induced by U18666A reproduces 
the outcome seen in Npc1− /− mice in regards to the inverse relationship 
between ACDase and STARD1 expression. Consistent with this link be-
tween ACDase and STARD1, cholesterol extraction by HMβCD prevents 
U18666A-mediated decrease ACDase expression, resulting in subse-
quent reversal of U18666A-induced STARD1 upregulation. Interest-
ingly, we observed a paralleled regulation between MLN64 and STARD1 
expression in response to U18666A, which could reflect the fact that 
both carriers exhibit strong affinity for cholesterol determined by their 
STAR domain [17,18]. These findings underscore that the down-
regulation of ACDase appears to be a consequence of lysosomal 
cholesterol accumulation in NPC fibroblasts or PMH incubated with 
U18666A. Although further work will be required to understand the 
basis for the ACDase repression in NPC disease, it is conceivable that 
cholesterol accumulation in lysosomes may affect membrane physical 
properties, leading secondarily to the modulation of ACDase expression. 
Whether fluidization of lysosomes reverses the ACDase repression in 
NPC disease remains to be investigated. To further establish a specific 
relationship between ACDase with STARD1 expression, we overex-
pressed ACDase in fibroblasts from patients with NPC. This approach, 
which increased ACDase levels, resulted in the subsequent down-
regulation of STARD1. Of interest, while our findings suggest that 
STARD1 upregulation contributes to mitochondrial cholesterol accu-
mulation, this event could be an additional consequence of impaired 
mitochondrial cholesterol metabolism. For instance, consistent with this 
possibility, reduced levels of CYP450scc (also known as CYP11A1) have 
been described in cerebellum of Npc1− /− mice, reflecting the disruption 
in neurosteroidogenesis and decreased levels of pregnenolone, the first 
steroid produced from mitochondrial cholesterol, in brain of Npc1− /−
mice [38]. 
SF-1 (NR5A1) and LRH-1 (NR5A2) are two orphan members of the 
Ftz-F1 subfamily of nuclear receptors. While LRH-1 is expressed in tis-
sues derived from endoderm, including intestine, liver and exocrine 
pancreas, as well as ovary, SF-1 is predominantly expressed in endocrine 
organs and brain [39]. As related members, both SF-1 and LRH-1 are 
known to regulate STARD1 [40–42]. Consistent with the tissue-specific 
expression of SF-1 and LRH-1, our findings reveal an increased expres-
sion of LRH-1 in liver from Npc1− /− mice and fibroblasts from NPC 
patients in line with the downregulation of ACDase, further establishing 
an inverse relationship between ACDase and LRH-1 that can account for 
the regulation of STARD1. In support for a causal role between LRH-1 
and STARD1, previous reports in human granulosa tumor cells indi-
cated that LRH-1 transactivates the STARD1 promoter through the − 105 
to − 95 site, while targeted loss of LRH-1 in granulosa cells decreased 
STARD1 mRNA levels and progesterone production in transgenic mice 
in response to human chorionic gonadotrophin, causing a failure to 
ovulate [43,44]. Similar to the ability of ACDase to preserve mito-
chondrial performance despite lysosomal cholesterol storage, recent 
findings linked lysosomal and mitochondrial dysfunction in NPC disease 
to mTORC1 hyperactivation [45]. Interestingly, genetic and pharma-
cological inhibition of mTORC1 improved mitochondrial function 
without correcting lysosomal cholesterol accumulation [45]. These 
findings suggest that the defects in mitochondrial cholesterol homeo-
stasis and function in NPC disease can be normalized independently of 
lysosomal cholesterol loading. 
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An interesting point that deserves further consideration is the rela-
tionship between the basal levels of ACDase and its enzymatic product 
sphingosine in NPC disease. Sphingosine is one of the glycosphingolipids 
whose levels increased in NPC disease [7,46]. As ACDase catalyzes the 
deacylation of ceramide to sphingosine, its lower expression would not 
account of the observed higher sphingosine levels in NPC disease. How 
can we reconcile increased sphingosine level with lower ACDase 
expression? Although the status of other CDases in NPC disease remains 
to be investigated, recent findings have reported lower expression of 
sphingosine kinase 1 in NPC disease [47]. As sphingosine is the substrate 
of sphingosine kinase 1, its downregulation may contribute to the higher 
levels of sphingosine in NPC disease. 
Overall, the present study analyzed the molecular players that 
contribute to the mitochondrial cholesterol accumulation in NPC dis-
ease, and revealed a key link between ACDase and STARD1 in this event. 
At the functional level, we show that the reexpression of ACDase in fi-
broblasts from patients with NPC disease lowers STARD1 expression and 
causes a decrease in mitochondrial cholesterol accumulation, which in 
turn results in replenishment of mGSH levels, improvement of mito-
chondrial routine performance, and decrease in ROS generation and 
protection against oxidative stress-dependent cell death. Thus, these 
findings imply that ACDase emerges as a novel opportunity for treat-
ment to prevent mitochondrial cholesterol loading and its known con-
sequences on mitochondrial function and antioxidant defense, which are 
of potential relevance in NPC disease. 
4. Materials and methods 
4.1. Study design 
This is a prospective study with the aim to examine the putative 
mechanisms of mitochondrial cholesterol accumulation, which is an 
additional feature of NPC disease besides the well-recognized accumu-
lation of cholesterol in endolysosomes. Npc1− /− mice was used as a 
model of NPC disease, which reproduces many of the pathological signs 
observed in patients, including hepatosplenomegaly, neurological de-
fects, cerebellar functional alterations, leading to motor impairment and 
premature death. In addition, fibroblasts from patients with NPC disease 
were used to address the relevance of the findings with Npc1− /− mice. 
The study included the isolation of mitochondria from liver and brain as 
well as the culture of PMH from Npc1− /− mice and fibroblasts from NPC 
patients. Most measurements, including western blots, confocal ana-
lyses, H&E and biochemical analyses were performed in an open 
fashion. To gain statistical power sample size was calculated based on 
previous and comparable studies in which a similar sample size reached 
statistically significance. The number of individual mice and experi-
ments with primary mouse hepatocytes or human fibroblasts from pa-
tients with NPC disease are indicated in Figure Legends. 
4.2. Npc1− /− model and Stard1 ΔHep mice 
Npc1− /− mice (NPC1NIH, BALB/cJ strain) were obtained from The 
Jackson Laboratories. At the time of weaning (21 days), mice were 
genetically identified by PCR using DNA prepared from tail-tips and 
following the genotyping protocols provided by the supplier, as 
described previously [7]. Liver-specific Stard1 knockout (Stard1ΔHep) 
mice were created by crossing Stard1f/f mice, which were generated by 
the Cre-lox technology, with Alb-Cre mice and have been recently 
characterized [23]. Stard1ΔHep and Stard1f/f littermates were used in this 
study to isolated primary hepatocytes. All procedures involving animals 
and their care were approved by the Ethics Committee of the University 
of Barcelona (protocol number 371/18) and were conducted in accor-
dance with institutional guidelines in compliance with national and 
international laws and policies. 
4.3. Fibroblasts from patients with NPC disease 
Fibroblasts from patients with NPC disease used have been previ-
ously described [7]. Briefly, cultured human skin fibroblasts from con-
trol individuals (HSF; GM5659D) and patients with NPC disease were a 
generous gift from Thierry Levade, Laboratoire de Biochimie Metabo-
lique, Institut Federatif de Biologie (CHU Toulouse, France) or obtained 
from Coriell Institute for Medical Research (GM03123, NJ, USA) and 
were grown at 37 ◦C in 5% CO2. DMEM (Gibco) culture medium was 
supplemented with 10% fetal bovine serum (FBS, Gibco, 10-270-106) 
and 10.000U/ml Penicillin-Streptomycin (Gibco, 15140-122). 
4.4. Primary mouse hepatocytes isolation 
PMH were isolated by collagenase perfusion at a flow rate of 7–9 ml/ 
min and cultured at a density of 2 × 105 cells in 12-well plates coated 
with rat tail collagen. Hepatocytes were cultured in DMEM/F12 culture 
media (Gibco, 21331-020) supplemented with 10% FBS for the first 3 h 
post isolation, together with 10.000U/ml Penicillin-Streptomycin 
(Gibco, 15140-122), 200 mM L-Glutamine (Gibco, 25030-024), 7.5 
mM D-Glucose (Sigma, G6152) and 150 mM Hepes pH 7.4 (Sigma). For 
subsequent treatments, FBS was replaced for 1 mM methionine (Sigma, 
M5308). 
4.5. In vitro treatments 
PMH from Npc1+/+ and human Npc+/+ control fibroblasts were 
treated with U18666A (2 μg/ml) or HMβCD (2 mM) for 16 h. In some 
other cases, PMH from Npc1− /− and Npc− /- fibroblast from NPC patients 
were treated with HMβCD as above for control PMH. 
4.6. ACDase overexpression 
Fibroblasts from NPC patients were transfected with cDNA to over-
express ACDase (ASAH1) (MGC Human ASAH1 Sequence-Verified cDNA 
Accession: BC016481 Clone ID: 3923451) commercially purchased from 
GE Dharmacon. Transfection. This was performed using Lipofect-
amine2000 (Invitrogen). Briefly, 250000 fibroblasts were incubated 
with the transfection mixtures containing 250 ng of the sobrexpression 
ACDase vector or the scrambled control-GFP vector. Cells were assayed 
48 h after transfection for mRNA and protein levels. 
4.7. Real time PCR 
Total RNA was isolated from fibroblasts with Trizol reagent 
following original protocol from Trizol’s Reagent (manufacter’s proto-
col). Quantitative Reverse Transcription Polymerase Chain Reaction 
(qRT-PCR) was performed using the iScript One-Step RT-PCR Kit with 
SYBR Green (Bio-Rad, Hercules, CA) following the manufacturer’s in-
structions. Each reaction was run in duplicate to determine the threshold 
(CT) for each mRNA, and the amount of each cDNA relative to the 
β-Actin endogenous control was determined using the 2-ΔΔCt method. 
The following primer sequences synthesized from Invitrogen were used: 
Gene Accession # Forward primer (5′-3′) Reverse primer (5′-3′) 
GFP L29345 CAGGAGCGCACCATCTTCTT CTTGTGCCCCAGGATGTTG 
ASAH1 (ACDase) NM_177924.5 AGTTGCGTCGCCTTAGTCCT TGCACCTCTGTACGTTGGTC 
ACTB NM_001101.5 TTGCCGACAGGATGCAGAA GCCGATCCACACGGAGTACT   
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4.8. Recombinant GST-PFO probe 
To assess an effective localization of cholesterol in membranes of 
liver, brain and liver tissues, we used a recombinant Perfringolysin O 
(PFO) fusioned with Glutathione-S-Transferase (GST-PFO). In tissues, 
PFO is able to track cholesterol of outer and inner membranes when 
these have more than 30% mol of cholesterol and the fusion with GST 
allows the detection by immunofluorescence techniques. The produc-
tion of recombinant GST-PFO probe has been described in [48]. The 
sequence to design the plasmid was from NCBI database: DNA M36704, 
the gen of PFO in the Clostridium perfringens genome. Additionally, the 
signal peptide was eliminated from the PFO gen to enable the intracel-
lular stance of the protein. The resulted sequence was synthesized into 
the plasmid pGEX 4T-1 (GenScript) between the BamHI and SmaI re-
striction sites. The plasmid was engineered to make a fusion protein with 
the GST tag. After bacterial production, and protein extraction and pu-
rification, the GST-PFO probe was dialyzed, concentrated, quantified 
and stored at − 80 ◦C. 
4.9. Filipin and GST-PFO staining 
Cryopreserved liver, brain and cerebellum samples from were cut on 
a cryostat at 14 μm thin sections and placed on glass slides. Sections 
were brought to RT for 30 min, fixed in 4% paraformaldehyde for 20 min 
and washed with PBS. For Filipin staining tissues were incubated with 
25 μg/mL Filipin (Sigma) over night at 4 ◦C protected from the light. 
After washing, slices were mounted with prolong antifade mountant 
(Dako). For GST-PFO staining, the sections were permeabilized with 
0.2% Triton X-100 in blocking buffer (5% goat serum + 1% BSA in PBS) 
for 2 h in a dark-humid chamber. Then, slices were incubated 3 h with 
the probe GST-PFO (20 μg/ml) in 1% Goat Serum containing 0.05% 
Triton X-100 in PBS. After washing × 3 with PBS, samples were incu-
bated O.N. at 4 ◦C with primary antibody Glutathione-STransferase 
(GST) (Santa Cruz). Secondary antibodies were diluted 1:200 in 1% 
Goat Serum containing 0.05% Triton X-100 in PBS and incubated for 90 
min at RT with the mix of anti-mouse Alexa fluor-532 (for GST). After 
washing, slices were incubated 5 min in sudan black 0.1% in 70% EtOH 
to minimize autofluorescence and mounted with prolong antifade 
mountant (Dako). Images for all samples were taken with a Leica TCS 
SP5 laser scanning confocal system with a 633 oil immersion objective 
APO CS numerical aperture 1.4 equipped with a DMI6000 inverted 
microscope. 
4.10. Mitochondria isolation 
Mitochondrial fraction was isolated from liver and brain by Percoll 
density grandient centrifugation as described previously [7,23]. Mito-
chondrial purity and cross contamination with extramitochondrial 
compartments was performed, as described previously [10,14]. 
Contamination of mitochondrial fraction with ER, plasma membrane 
and early and late endosomes was excluded by analisis of GRP78, 
ATPaseα1, Rab5A, and Rab11, respectively, (Supplemetary Figure 9). 
Alternatively, PMH and fibroblasts were fractionated into cytosol and 
mitochondria by digitonin permeabilization as described previously 
[10]. Briefly, cells were fractionated into cytosol and mitochondria by 
selectively permeabilizing the plasma membrane with digitonin and 
subsequent centrifugation through an oil layer with 10% trichloroacetic 
acid (TCA) at the bottom. Aliquots of the total, cytosolic and mito-
chondrial fractions were kept on ice for determination of GSH levels by 
the recycling method as previously described [10]. 
4.11. Cholesterol measurements 
Total cholesterol determination in homogenates (1 mg/ml) or 
mitochondrial extracts (2.3 mg/ml) was performed upon saponification 
with alcoholic KOH followed by water:hexane 1:2 extraction. Hexane 
phase was evaporated in a speed vacuum and used for cholesterol 
measurement. Unesterified cholesterol was determined from the same 
unsaponified samples and analyzed by HPLC using Bondapak C18 10 μm 
reversed-phase column (30 cm × 4 mm inner diameter; Waters, Cro-
matografia, S.A., Barcelona, Spain), and 2-propanol⁄acetonitrile⁄water 
(60:30:10) as mobile phase at a flow rate of 1 ml⁄min as described [26]. 
The amount of cholesterol was calculated from standard curves and the 
identity of the peaks was confirmed by spiking the sample with known 
standards. 
4.12. Measurement of fluorescence anisotropy 
Fluidity of mitochondrial membranes was evaluated by fluorescence 
anisotropy of mitochondria-bound dye DPH. DPH (20 mM in tetrahy-
drofuran) was first diluted 100 times with 10 mM Tris-HCl, 150 mM KCl, 
1 mM EDTA, pH 7.4. Subsequently, DPH was injected into stirred 
mitochondrial suspensions (0.5 mg/ml) and the mixture was incubated 
for 30 min at 37 ◦C. Fluorescence polarization was measured in a Hitachi 
spectrofluorometer at wavelengths of 366 nm for excitation and 425 nm 
for emission. The results are expressed as anisotropy units (r), where r =
(I0/I90)/(I0+2I90). I0 and I90 represent the intensities of light when 
polarizers were in parallel or perpendicular orientation, respectively. 
Light scattering and intrinsic fluorescence were routinely corrected by 
subtracting the signal obtained from unlabeled samples and the fluo-
rescence of the buffer plus label alone. 
4.13. ROS generation and cell viability 
For ROS production and cell viability assays, fibroblasts were treated 
with hydrogen peroxide (H2O2) 1 mM for 24 h. For ROS production 
analysis, cells were then incubated with the cell-permeable CellROX 
Deep Red reagent (5 μM) solution for 30 min at 37 ◦C in the dark, 
washed with PBS and evaluated by fluorescence spectroscopy using the 
Tecan Infinite® 200 PRO multi-mode microplate reading (640 nm for 
excitation and 665 nm for emission). The fluorescence was normalized 
by protein content, determined by BCA protein assay. The induction of 
ROS was calculated with respect to control samples. For cell viability 
analysis, cells were incubated with Höechst (10 μg/ml) solution for 20 
min at 37 ◦C in dark, washed with PBS, fixed with formalin 10% and 
evaluated in a fluorescence microscope Leica TCS-SPE DM2500. 
Viability was calculated as the difference between the final number of 
cells and the cells present in the non-treated condition. 
4.14. Western blot analysis 
100 mg of liver were homogenized with a pestle homogenizer in 1 ml 
of homobuffer (70 mM saccharose, 220 mM mannitol, 2 mM Tris-HCl pH 
7.4, 0,1 mM EDTA, 0.1% fatty acid free BSA) supplemented with pro-
tease and phosphatase inhibitors (Roche). Liver homogenates were 
diluted 4 times with RIPA lysis buffer (Sigma) with anti-proteases and 
anti-phosphatases. Cells were washed with PBS and lysed with ice-cold 
RIPA lysis buffer supplemented with protease and phosphatase in-
hibitors. Samples were incubated 15min at 4 ◦C, vortexed and spun 
down for 5min at 10000 rpm. All supernatants were collected and 
quantified for protein concentration using Quick-Bradford reagent (Bio- 
Rad) and 20–50 μg of protein were subjected to 4–12% SDS–polyacry-
lamide gel electrophoresis (SDS-PAGE) (Bio-Rad, XT-Criterion). Proteins 
were electrotransferred at 4 ◦C onto Hybond ECL nitrocellulose mem-
branes (Amersham) and 5% BSA solution in TBS-Tween was used to 
block the membranes for 1 h at room temperature. Membranes were 
incubated overnight with the following primary antibodies: anti-PDI 
(Cell Signaling, 24465), anti-CHOP (Cell Signaling, 2895S), anti- 
Phospho eiF2A (Cell Signaling, 9721S), anti-eiF2A (Cell Signaling, 
9722) and anti-StARD1 (Abcam, ab58013), anti-BIP (Stressgen, 
SPA826), anti-XBP1 (Santa Cruz, CS-8015) and anti-Mln64 (Santa Cruz 
SC-292868), ACDAse (Sigma, SAB3500293), LRH-1 (Santa Cruz, Cs- 
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393369) and anti-β-Actin HRP-conjugated (Sigma, A3854). Membranes 
were thoroughly washed with TBS-Tween and incubated for 45min with 
their respective HRP-conjugated secondary antibodies. Pierce ECL 
Western Blotting Substrate (Thermo Scientific) was used to develop the 
membranes. Images were digitally captured by LAS4000 (GE Health-
care) and optical density was analyzed with ImageJ software. 
4.15. Immunofluorescence and laser confocal imaging 
PMH were fixed for 15min with 3.7% paraformaldehyde and per-
meabilized for 5min with 0.2% saponin dissolved in 0.5% BSA-fatty acid 
free (FAF) in PBS commercial buffer. Cells were blocked with 1% BSA 
FAF for 15 min. Cytochrome c (Cytc) (BD Pharmigen, #556432) and 
Lamp2 (Abcam, #ab13524) primary antibodies were incubated over-
night in BSA 1% followed by a secondary antibody for 1 h at room 
temperature in BSA 0.1%. Filipin (50 mg/ml, Sigma) was added during 
the secondary antibody incubation and the following steps were per-
formed in the dark. Stained samples were embedded in fluoromont 
(Sigma) and digital images were taken in a Leica SP2 laser scanning 
confocal microscope equipped with UV excitation, an argon laser, a 
633/1.32 OIL PH3 CS objective and a confocal pinhole set at 1 Airy unit. 
All the confocal images shown were single optical sections. Scale bar 
represents 25 μm. Percentage of cholesterol mass containing mito-
chondria was analyzed with the Colocalization nBits nimages plugin 
(Confocal Microscopy Unit, Facultad de Medicina, Universidad de Bar-
celona) in the Image J Software in 5 consecutive images of each 
experimental condition as described before [49]. This plug-in sofware 
highlights the colocalized points of two images of 32-bits, and returns 
the integrated densities of total green (higher than the threshold) and 
the green from colocalized points and total red (higher than the 
threshold) and red from colocalized points. Two points are considered as 
colocalized if their respective intensities are strictly higher than the 
threshold of their channels and if their ratio of intensity is strictly higher 
than the ratio setting value, which have been defined at 50%. Percentage 
of green colocalization with red or red colocalization with green is 
calculated as the ratio of green colocalized points divided by total green 
multiplied per 100 or as the ratio of red colocalized points divided by 
total red multiplied per 100, respectively. 
4.16. Extracellular flux analyses 
In vivo real-time mitochondrial respiration (OCR) was monitored 
with the Seahorse XFe24 Flux Analyser (Seahorse Bioscience) according 
to the manufacturer’s instructions. Fibroblasts were seeded at 20000 
fibroblasts/well density in 24-well plates and cultured overnight in 
DMEM culture media. For assessment of the real-time OCR, cells were 
incubated with unbuffered assay media (XF Media Base with 10 mM 
glucose, 1 mM L-glutamine and 1 mM sodium pyruvate) followed by a 
sequential injection of 2 μM oligomycin, 1 μM carbonyl cyanide-4- 
(trifluoromethoxy) phenylhydrazone and 1 μM antimycin A plus Rote-
none. OCR measurements were normalized to μg of total protein 
following BCA protein assay. 
4.17. Statistical analyses 
Statistical analyses were performed using GraphPad Prism 6 
(Graphpad Software Inc). Unpaired Student’s t-test (two tailed) was 
performed between two groups and one or two-way ANOVA followed by 
Tukey’s Multiple Comparison test were used for statistical comparisons 
between three or more groups, with p < 0.05 considered as significant 
(*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). The corre-
sponding number of experiments is indicated in the figure legends. Data 
in graphs are shown as mean ± SEM. 
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